Monday, August 25th, 2025
Stock Profile: ATXS
ATXS Logo

Astria Therapeutics, Inc. (ATXS)

Market: NASD | Currency: USD

Address: 75 State Street

Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema. The company is also developing STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, an immune disorder associated with loss of skin barrier function and itching. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Show more




📈 Astria Therapeutics, Inc. Historical Chart






📊 Statistics





💰 Dividend History


Year Annual Yield (%) Total Amount Current Yield (%) Ex Date Pay Date Particulars
2021 - $0.166667 - 2021-08-20 - Stock split
Total Amount for 2021: $0.166667
2018 - $0.100000 - 2018-12-31 - Stock split
Total Amount for 2018: $0.100000


📅 Earnings & EPS History for Astria Therapeutics, Inc.


DateReported EPS
2025-11-14 (estimated upcoming)-
2025-08-12-0.57
2025-05-13-0.58
2025-03-11-0.44
2024-11-13-0.42
2024-08-12-0.43
2024-05-09-0.38
2024-03-04-0.94
2023-11-13-0.63
2023-08-07-0.45
2023-05-11-0.4
2023-03-22-0.72
2022-11-10-0.87
2022-08-09-0.86
2022-05-12-1.18
2022-03-10-0.44
2021-11-10-0.61
2021-08-09-5.34
2021-05-13-45.6
2021-03-11-2.64
2020-11-12-3.24
2020-08-10-3.05
2020-05-12-2.87
2020-03-10-3.18
2019-11-07-3.17




📰 Related News & Research


No related articles found for "astria therapeutics".